Compare Docusign Inc (DOCU) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Gilead Sciences, Inc. — how do they compare? Docusign Inc trades at $71.49 (market cap $13.35B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 13.7× Docusign Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Gilead Sciences, Inc. for 111 Days on average.
| DOCU | GILD | |
|---|---|---|
Market Cap | $13.35B | $182.40B |
Volume | 3,158,858 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $73.14 | $155.80 |
52-Week Low | $41.75 | $116.74 |
Typical Hold Time | 71 Days | 111 Days |
Enterprise Value | $12.76B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DocuSign (DOCU) trades at $68.9, up 1.0% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.16 surpassing the $1.09 forecast. Revenue growth remains solid, reaching $2.98B in 2025, while profitability has improved significantly, with net income margin at 9.82%. Recent news highlights strong momentum, including a 50.8% stock surge over three months and leadership in IDC's integrated signing workflow software assessment (IDC MarketScape, August 2026).
The outlook for DOCU is cautiously optimistic, driven by AI-powered Intelligent Agreement Management adoption and operating leverage. However, risks include saturation in the e-signature market, insider selling activity, and a high P/E ratio of 42.01. Analyst consensus is mixed, with a Hold rating predominating (64.29%) and a price target of $68.75, slightly below the current price. Investors should weigh strong cash flow generation against valuation concerns and competitive pressures.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
